ReviewDrugs2013
Teduglutide: a review of its use in the treatment of patients with short bowel syndrome.
Review in Drugs, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Assessing the health-related quality of life and clinical effect in children with short bowel syndrome receiving teduglutide treatment.BMC pediatrics · 2026Article
- Qualitative Research for the Development of Three New Quality of Life and Treatment Impact Questionnaires for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF).Digestive diseases and sciences · 2026Article
- Effectiveness and Safety of Teduglutide Treatment in Adult Patients with Short Bowel Syndrome: A Case Series and Review of Current Evidence.Journal of clinical medicine · 2026Article
- Real-world effectiveness and safety of teduglutide in patients with short bowel syndrome.World journal of gastrointestinal pharmacology and therapeutics · 2026Article
- Navigating the Prognosis and Functional Recovery of Short Bowel Syndrome: A Mentored Review.Digestive diseases and sciences · 2026Review
- Glucose-Dependent Effects of Exogenous Glucagon-Like Peptide-2 on Circulating Glucagon Levels in Healthy Men.Journal of the Endocrine Society · 2026Article
- Incretin hormones and obesity.The Journal of physiology · 2025Review
- Enteroendocrine cells: the gatekeepers of microbiome-gut-brain communication.NPJ biofilms and microbiomes · 2025Review
- Efficacy of Teduglutide in Pediatric Short Bowel Syndrome: Association with Citrulline Levels and Anatomical Location of Remnant Small Intestine.Children (Basel, Switzerland) · 2025Article
- Article
- Normothermic Preservation of the Intestinal Allograft.Gastroenterology clinics of North America · 2024Review
- Managing fluid balance and nutritional status in a short bowel syndrome patient awaiting intestinal transplant: a case report.European journal of clinical nutrition · 2024Article
- Computational peptide discovery with a genetic programming approach.Journal of computer-aided molecular design · 2024Article
- Computational Peptide Discovery with a Genetic Programming Approach.Research square · 2023Article
- Expression, Purification and Characterization of Functional Teduglutide Using GST Fusion System in Prokaryotic Cells.Advanced pharmaceutical bulletin · 2023Article
- New Insights into the Structure and Function of Class B1 GPCRs.Endocrine reviews · 2023Article
- Improvement in metabolic indices including thyroid hormones via enhanced absorption of nutrients by Teduglutide in short bowel syndrome.International journal of surgery case reports · 2022Article
- Article
- An updated overview of glucagon-like peptide-2 analog trophic therapy for short bowel syndrome in adults.The Journal of international medical research · 2022Review
- Therapeutic peptides: current applications and future directions.Signal transduction and targeted therapy · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The recombinant analogue of human glucagon-like peptide-2 (GLP-2) teduglutide (Gattex(®), Revestive(®)) is a novel therapy for short bowel syndrome (SBS). GLP-2 is a naturally occurring hormone that regulates the growth, proliferation and maintenance of cells lining the gastrointestinal tract. Subcutaneous teduglutide is the first long-term medical therapy approved for the treatment of adult patients with SBS who are dependent on parenteral support (parenteral nutrition and/or intravenous fluids). In a pivotal, double-blind, multicentre, phase III study in adult patients with SBS who were dependent on parenteral support, a significantly higher proportion of teduglutide 0.05 mg/kg/day recipients than placebo recipients achieved at least a 20% reduction from baseline in weekly parenteral support volume at week 20 and maintained at week 24 (primary endpoint). The overall mean reduction in weekly parenteral support volume from baseline was greater in patients who received teduglutide compared with those who received placebo. Additionally, more teduglutide-treated patients achieved at least a one-day reduction in parenteral support than those receiving placebo. Subcutaneous teduglutide had an acceptable tolerability profile; the most frequently reported adverse events were of gastrointestinal origin, consistent with the underlying disease condition and the known mechanism of action of teduglutide.
Indexed as
Identifiers
23729002What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.